Protein Profiles of Pretransplant Grafts Predict Early Allograft Dysfunction After Liver Transplantation From Donation After Circulatory Death

Transplantation. 2020 Jan;104(1):79-89. doi: 10.1097/TP.0000000000002787.

Abstract

Background: Predicting the development of early allograft dysfunction (EAD) following liver transplantation (LT) remains challenging for transplant clinicians. The objectives of this study are to investigate the potential relationship between the protein profiles of pretransplant grafts and the onset of EAD, and then combine with clinical parameters to construct a mathematically predictive model.

Methods: Clinical data of 121 LT procedures from donation after circulatory death at the authors' center were analyzed. The expression levels of 7 studied proteins were determined by immunohistochemistry. Another independent cohort of 37 subjects was designed for further validation of the predictive model.

Results: With an incidence of 43.0% (52/121), EAD was linked to significantly increased risk of acute kidney injury and renal replacement therapy, as well as reduced 6-month patient and liver graft survival. Allograft weight and high intrahepatic vascular endothelial growth factor (VEGF) expression were identified as independent risk factors of EAD and survival outcomes. Liver grafts with high VEGF expression exhibited delayed functional recovery within the first postoperative week. The combination of VEGF overexpression and EAD yielded the highest frequency of renal dysfunction and the worst survival. Based on allograft weight and intrahepatic VEGF expression, an EAD risk assessment model was developed. The incidence of EAD differed significantly between grafts with risk scores ≥-1.72 and <-1.72. The model functioned well in the validation cohort.

Conclusions: Pretransplant intrahepatic protein profiling contributes to the estimation of early graft performance and recipient outcomes following LT. The predictive model could allow for an accurate prediction of EAD.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Acute Kidney Injury / epidemiology*
  • Acute Kidney Injury / ethnology
  • Acute Kidney Injury / therapy
  • Adult
  • Allografts / metabolism*
  • Cohort Studies
  • End Stage Liver Disease / mortality
  • End Stage Liver Disease / surgery*
  • Female
  • Graft Survival
  • Humans
  • Immunohistochemistry
  • Incidence
  • Liver / metabolism*
  • Liver Transplantation / adverse effects*
  • Living Donors
  • Male
  • Middle Aged
  • Models, Statistical
  • Preoperative Period
  • Primary Graft Dysfunction / complications
  • Primary Graft Dysfunction / epidemiology*
  • Renal Replacement Therapy / statistics & numerical data
  • Risk Assessment / methods
  • Risk Factors
  • Survival Analysis
  • Transplantation, Homologous / adverse effects
  • Vascular Endothelial Growth Factor A / analysis
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A